جست‌وجوی استاد و پژوهشگر

Nicole C Duboisمشاهده پروفایل

دانشیار

• Stem Cell Biology
• Cardiovascular Development
• Regenerative Medicine
• +۴ مورد دیگر

Nicole C Dubois is an Associate Professor in the Department of Cell, Developmental & Regenerative Biology at the Icahn School of Medicine at Mount Sinai. Her research focuses on understanding early heart development and leveraging this knowledge to advance regenerative medicine approaches for cardiac diseases. She holds a BA from the Swiss Federal Institute of Technology Zurich (ETHZ) and a PhD from the Swiss Institute for Experimental Cancer Research (ISREC), followed by postdoctoral training at the McEwen Centre for Regenerative Medicine in Toronto. Dr. Dubois’ work spans multidisciplinary training areas including Development, Regeneration, and Stem Cells (DRS). Her research emphasizes the directed differentiation of pluripotent stem cells into specialized cardiac cell types, with particular attention to cardiomyocyte maturation, cardiac progenitor stabilization, and the molecular mechanisms governing chamber-specific cardiac development. She explores innovative strategies such as engineered extracellular vesicle-encapsulated gene delivery systems and optimized mRNA translation to enhance therapeutic applications for heart failure and cardiotoxicity. Her studies integrate genomic approaches, including chromatin architecture mapping and transcriptomic analysis, to decode how developmental pathways regulate cardiac cell fate and function. Work on Notch signaling, PPARδ activation, and Wnt/β-catenin modulation highlights her focus on molecular levers for cardiac repair. Recent projects address individualized predictions of drug-induced cardiotoxicity and the role of sphingolipid metabolism in myocardial infarction recovery. Leveraging in vitro models and murine systems, her lab bridges basic science discoveries with translational applications, aiming to address unmet clinical needs in heart disease. Ongoing efforts include refining exosome-AAV vectors for evading immune responses and improving cardiac gene delivery efficacy.

• Drug Discovery
• Fibroproliferative Diseases
• Pharmacology
• +۴ مورد دیگر

Selim Cellek is a Professor of Health and Biomedicine at Anglia Ruskin University (ARU), leading the Drug Discovery Group within the Medical Technology Research Centre (MTRC). He holds a Medical Degree from Hacettepe University and a PhD in Pharmacology from the University of London, followed by postdoctoral research at University College London (UCL). His career includes roles at GlaxoSmithKline (GSK), UCL, and Cranfield University prior to joining ARU in 2015. Research Interests: Phenotypic assays for drug discovery Fibroproliferative diseases (e.g., Peyronie’s disease, benign prostatic hyperplasia) Urogenital tract physiology and nitrergic neurotransmission Diabetic autonomic neuropathy His work focuses on translating basic science into clinical applications, particularly targeting fibrotic disorders through novel drug development. Recent Articles: Recent studies emphasize anti-fibrotic drug development, leveraging phenotypic screening and high-throughput assays. Key themes include myofibroblast inhibition, synergistic drug combinations (e.g., PDE5 inhibitors and tamoxifen), and repurposing FDA-approved drugs. Awards & Grants: Fellowship: British Pharmacological Society Membership: European Society for Sexual Medicine Consultancy to pharmaceutical companies in urogenital and diabetes therapeutic areas Advising & Labs: Leads the Drug Discovery Group at MTRC, focusing on translational medicine. Collaborates with industry on anti-fibrotic drug pipelines and digital health solutions for dementia care (e.g., SMART4MD app). Future Work: Expanding research into fibrosis pathophysiology, optimizing phenotypic screening platforms, and advancing treatments for chronic fibrotic conditions like Peyronie’s disease and diabetic neuropathy.

Vikram Shakkottaiمشاهده پروفایل

استاد

• Neurology
• Neurodegenerative Diseases
• Cerebellar Physiology
• +۳ مورد دیگر

Dr. Vikram Shakkottai is a Professor in the Department of Neurology at UT Southwestern Medical Center, specializing in cerebellar ataxias. He joined UT Southwestern in 2021 and co-leads the Resident Research Track to train future clinician-scientists. His research focuses on identifying how neuronal physiology contributes to motor dysfunction and degeneration in cerebellar ataxia, with particular emphasis on ion channel dysfunction and Purkinje neuron excitability. His work has demonstrated shared therapeutic strategies targeting these pathways across multiple ataxia models. Education: MD from Christian Medical College, Vellore (India); PhD from UC Irvine Residency: Neurology at Washington University/Barnes-Jewish Hospital Fellowship: Movement Disorders at University of Michigan Research interests include cerebellar physiology, ion channelopathies in neurodegeneration, and translational therapies for spinocerebellar ataxias (SCAs). His lab employs advanced imaging, genetic analysis, and cellular models to study disease mechanisms. Key findings include identifying olivary hypertrophy and intrinsic membrane hyperexcitability as biomarkers for SCA1 progression. Publications highlight advancements in MRI-based progression metrics, genetic discovery (e.g., SCA27B), and drug repurposing strategies. Collaborations span clinical trials, stem cell models, and multi-center studies to accelerate ataxia research. The Shakkottai Lab actively seeks researchers to join their interdisciplinary efforts. Notable contributions include the SARA (Scale for the Assessment and Rating of Ataxia) utility studies and development of organoid models for ataxia research. His work bridges basic science and clinical care, aiming to improve diagnosis and treatment options for cerebellar ataxia patients.

Frédéric Rieux-Laucatمشاهده پروفایل

استاد پژوهشی

• Immunology
• Autoimmune Diseases
• Immunodeficiencies
• +۵ مورد دیگر

Frédéric Rieux-Laucat is a Research Professor and Team Leader at the Institut Imagine , focusing on the immunogenetics of pediatric autoimmune diseases. His work explores mechanisms underlying self-tolerance defects in primary immunodeficiencies and hyperimmune syndromes, with a focus on Autoimmune Lymphoproliferative Syndrome (ALPS), IPEX, and severe combined immunodeficiencies (SCID). Key research areas include FAS gene mutations, regulatory T cell dysfunction, STING pathway abnormalities, and cytokine dysregulation in autoimmune pathogenesis. His studies integrate clinical samples from patients with rare immune disorders, alongside animal and cellular models. Recent work has identified genetic modifiers like DOCK11, SOCS1, and PTPN2 in autoimmune onset, and contributed to understanding type I interferon deficiencies in severe COVID-19. He has trained a multidisciplinary team of researchers, including post-doctoral fellows, PhD candidates, and clinical collaborators. Key research themes include molecular mechanisms of lymphocyte apoptosis, regulatory T cell biology, and translational approaches to diagnose and treat immune dysregulation syndromes. His team’s discoveries bridge basic immunology to clinical applications, including biomarker development for primary immunodeficiencies and personalized therapies for autoimmune conditions.

Mahmoud Labibمشاهده پروفایل

مدرس

• Cancer Diagnostics
• Nanotechnology
• Biomedical Engineering
• +۳ مورد دیگر

Dr. Mahmoud Labib is a Lecturer at the Peninsula Medical School (Faculty of Health) at the University of Plymouth. His expertise lies in developing innovative diagnostic and therapeutic approaches for cancer, leveraging nanotechnology and microfluidics. He holds a Ph.D. in Biotechnology from Lund University (2009) and has conducted postdoctoral research across institutions in Canada, the US, and the UK, including roles at the University of Toronto and Northwestern University. Education: Ph.D. in Biotechnology, Lund University, Sweden (2009) Postdoctoral Studies: Western University (Canada), University of Ottawa (Canada), University of Toronto (Canada), and Northwestern University (USA) Research Interests: Dr. Labib focuses on advancing cancer diagnostics and therapeutics , with a particular emphasis on nanotechnology-based platforms for detecting biomarkers in liquid biopsies. His work integrates microfluidic devices, immunomagnetic cell sorting, and aptamer technologies to profile rare cells such as circulating tumor cells and tumor-reactive lymphocytes. His innovations aim to improve early detection, precision medicine, and therapeutic delivery systems. Articles Trends: His recent publications highlight advancements in microfluidic systems for high-throughput screening, magnetic cytometry for rare cell analysis, and nanomaterial-enabled detection of cancer-related biomarkers. These studies underscore his contribution to translating nanotechnology into clinical diagnostics. Labs/Teams: His research is conducted within the Peninsula Medical School’s interdisciplinary environment, collaborating with teams specializing in biomedical engineering and oncology. His lab develops cutting-edge tools for single-cell analysis and biomarker discovery. Teaching: At Plymouth, he teaches modules in physiology, renal systems, and cardiac muscle biology to medical and diagnostic radiography students.

Ville Männistöمشاهده پروفایل

استاد

• Liver diseases
• Steatotic liver disease
• Metabolic dysfunction-associated steatotic liver disease (MASLD)
• +۶ مورد دیگر

Professor Ville Männistö is a leading academic in gastroenterology and hepatology at the University of Eastern Finland, holding the Professorship of Gastroenterology since September 2024. He is affiliated with the Institute of Clinical Medicine within the School of Medicine, Faculty of Health Sciences. His academic career includes roles as Research Director, Clinical Researcher, and head of gastroenterology specialization training programs at the University of Eastern Finland and Kuopio University Hospital. He completed his Licentiate of Medicine (2008), MD (2016), and became a Docent in Gastroenterology (2021). His research focuses on liver disease epidemiology, particularly metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD). Key areas include fibrosis progression mechanisms, population-level liver risk stratification, and the synergistic effects of metabolic and alcohol-related factors. He has pioneered the CLivD risk score for liver-related event prediction and contributed to understanding genetic and environmental influences on liver health. Professor Männistö leads large-scale cohort studies such as the METSIM study tracking liver health in Eastern Finnish men, and has published extensively on biomarkers (e.g., indole-3-propionic acid), metabolic signatures, and clinical outcomes. His work integrates genetic, metabolic, and epidemiological data to advance early detection and prevention strategies for severe liver outcomes. His research also addresses global health challenges like rising inflammatory bowel disease prevalence and the evolving terminology of liver diseases. He collaborates internationally on projects such as the EU-funded METSIM study and liver metabolomics initiatives.

Botond Roskaمشاهده پروفایل

استاد

• Gene therapy
• Eye
• Retina
• +۷ مورد دیگر

Botond Roska is a Professor at the Faculty of Science, University of Basel, Switzerland, and previously served as Professor at the Faculty of Medicine, University of Basel since 2014. He is the Founding Director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB), established in 2018. His academic career includes serving as Senior Group Leader (2010-2019) and Junior Group Leader (2005-2010) at the Friedrich Miescher Institute in Basel. Born in 1969 in Hungary, Roska obtained his M.D. at the Semmelweis Medical School, a Ph.D. in neurobiology from the University of California, Berkeley, and studied genetics and virology as a Harvard Society Fellow at Harvard University and Harvard Medical School. Dr. Roska's research focuses on understanding the visual system at the level of cell types and circuits, with particular emphasis on the retina, thalamus, and cortex. His work aims to find ways to repair visual dysfunction and restore vision in blind individuals. He investigates how the organization of cell types and circuits in the nervous system, when combined with cellular engineering, can be used to design new therapies to fight blindness. Analysis of Roska's recent publications reveals a strong focus on single-cell resolution studies of the retina, development of gene therapy approaches for vision restoration, and detailed mapping of visual neural circuits. His work spans multiple disciplines including neuroscience, ophthalmology, genetics, and molecular biology, with a clear translational focus toward developing treatments for visual impairments. Dr. Roska has received numerous prestigious awards throughout his career: 1997: Fulbright Fellow 2001: Bearden Memorial Award for Biophysics 2002: Harvard Junior Fellow 2006: Marie Curie Excellence Grant 2009: EMBO Young Investigator 2010: ERC Starting Grant and VIVA Award 2011: Alcon Award and EMBO membership 2013: Alfred Vogt Award 2015: ERC Advanced Grant 2016: Cogan Award 2018: Bressler Prize and Alden W. Spencer Award 2019: Louis-Jeantet Prize, Order of Saint Stephen of Hungary, Cloëtta Prize, and Semmelweis Budapest Award 2020: ERC Advanced Grant and Körber European Science Prize 2024: Wolf Prize in Medicine (for sight-saving and vision restoration to blind people using optogenetics) As a principal investigator, Roska has secured significant research funding including multiple ERC grants (Starting Grant in 2010, Advanced Grants in 2015 and 2020), a Marie Curie Excellence Grant, and the VIVA Award. His laboratory has mentored numerous researchers who have gone on to publish impactful work in top-tier journals. The collaborative nature of his research is evident from the multi-institutional authorship of his publications. Dr. Roska founded and directs the Institute of Molecular and Clinical Ophthalmology Basel (IOB), which brings together basic scientists and clinicians to develop treatments for eye diseases. His laboratory employs advanced techniques including single-cell analysis, viral vector engineering, optogenetics, and neural circuit mapping to advance our understanding of the visual system and develop novel therapeutic approaches.

Duda Dan Gabrielمشاهده پروفایل

استاد

• Liver Cancer Therapeutics
• Immunotherapy
• Tumor Microenvironment Analysis
• +۵ مورد دیگر

Dan Gabriel Duda is a Professor of Radiation Oncology at Harvard Medical School (HMS) and Principal Investigator at the Massachusetts General Hospital (MGH) Research Institute. He holds leadership roles as Director of Translational Research in GI Radiation Oncology at MGH and Secretary General of the International Association of Surgeons, Gastroenterologists, and Oncologists (IASGO). His research focuses on tumor microenvironment interactions, particularly in liver cancers, aiming to develop combination therapies involving immunotherapy and radiotherapy. Duda has authored over 280 publications with an h-index of 74 and is recognized as a top 2% scientist globally. He earned a DMD from the University of Medicine Iasi (1993) and a PhD from Tohoku University (2001), followed by postdoctoral training at MGH/HMS. **Education**: DMD, University of Medicine Iasi, Romania (1993) PhD in Medical Sciences (Gastrointestinal Surgery), Tohoku University (2001) **Research Interests**: Duda’s lab explores mechanisms of tumor progression and treatment resistance in liver cancers. Key areas include: Biomarker development for therapeutic response and toxicity Preclinical models of hepatocellular carcinoma and cholangiocarcinoma Combination therapies targeting tumor microenvironment (angiogenesis, immunosuppression) Validation of immunotherapy and radiotherapy synergies **Awards**: 2021 AAAS Fellow (Medical Section) 2020 AIMBE College of Fellows Inductee 2021 Doctor Honoris Causa (University of Medicine Iasi) Multiple IASGO and MGH awards for research excellence **Advising & Grants**: Supervised over 80 trainees and holds grants from NCI, DOD, and industry partnerships. Serves on review panels (e.g., NCI Study Sections, SWOG Network). **Labs/Teams**: Leads the Duda Lab within the Steele Laboratories at MGH, focusing on translational oncology and liver cancer research.

• Bioinformatics
• Computational Genomics
• Transcriptional Regulation
• +۴ مورد دیگر

Zhiping Weng is a Professor and Chair of the Department of Genomics and Computational Biology at the University of Massachusetts Chan Medical School. She holds the Li Weibo Chair in Biomedical Research and is affiliated with the T.H. Chan School of Medicine and Morningside Graduate School of Biomedical Sciences. Her research focuses on computational biology, genomics, and systems biology, with a particular emphasis on understanding gene regulation, epigenomics, and small RNA biology. Dr. Weng earned her B.S. in Electrical Engineering from the University of Science and Technology of China (1992) and her Ph.D. in Biomedical Engineering from Boston University (1997). She joined UMass Chan Medical School in 2008 to establish the Program in Bioinformatics and Integrative Biology. Her research integrates computational methods with high-throughput genomics data to study transcriptional regulation, protein interactions, and small RNA mechanisms. Key projects include developing tools for predicting transcription factor binding sites, analyzing nucleosome positioning, and modeling protein complexes. Her lab also explores the role of piRNAs and miRNAs in transposon silencing and developmental processes. Recent work includes studies on tRNA sequencing, koala retrovirus evolution, and the functional annotation of regulatory elements across species. Her contributions span bioinformatics tool development (e.g., ZDOCK for protein docking) and collaborative efforts in genome-wide studies like ENCODE. Dr. Weng advises students and postdocs in computational biology and collaborates extensively on epigenetic and systems biology projects. Her lab is part of the broader genomic research community at UMass Chan, contributing to advancements in personalized medicine and functional genomics.

Michael Hildebrandمشاهده پروفایل

استاد

• Pain Research
• Neuroscience
• Translational Medicine
• +۲ مورد دیگر

Michael Hildebrand is a Professor in the Department of Neuroscience at Carleton University and an Affiliate Investigator at The Ottawa Hospital. He serves as Associate Vice-Provost (Graduate Student Affairs), overseeing graduate policies, student crisis mediation, and thesis defense processes across the university. His educational background includes a PhD in neurophysiology from the University of British Columbia (UBC), followed by an industrial R&D fellowship at NeuroMed Pharmaceuticals and an academic postdoctoral fellowship at Sick Kids Hospital. Hildebrand's research focuses on spinal mechanisms of pain processing using molecular, pharmacological, electrophysiological, and behavioral approaches. His lab bridges translational gaps between basic science and clinical needs by studying acute/chronic pain states in both rodent and human spinal cord models. Key interests include sexual dimorphism in pain pathways , T-type calcium channel functions , and NMDA receptor subunit contributions to identify novel pain treatment targets. Analysis of his 15 most recent publications reveals dominant trends in sex-specific pain mechanisms, human spinal cord translational models, and molecular targets like calcium channels and NMDA receptors. His work consistently integrates rodent and human tissue studies to address chronic pain's clinical challenges. Scientific recognition includes: Ronald Melzack, Canadian Journal of Pain Paper of the Year Award (2023) Hildebrand mentors undergraduate, graduate, and postdoctoral researchers while securing major funding from NSERC, CIHR, MITACS, and industry partners. His leadership extends to national roles including Chair of the Canadian Pain Society's Scientific Program Committee. The Hildebrand Lab operates within Carleton's Health Sciences Building, utilizing pioneering human spinal cord preclinical assays alongside animal models to investigate pain mechanisms and therapeutic interventions.

Serdar Bozdagمشاهده پروفایل

دانشیار

• Machine Learning
• Computational Biology
• Bioinformatics
• +۵ مورد دیگر

Serdar Bozdag is an Associate Professor in the Department of Computer Science and Engineering at the University of North Texas, with a joint appointment in Mathematics. He serves as Director of the Center for Computational Life Sciences, focusing on interdisciplinary research at the intersection of computational methods and biological systems. His research expertise spans machine learning applications in bioinformatics, multi-omics data integration, and network biology. Key areas include developing algorithms for disease biomarker discovery, integrating genomic, transcriptomic, and clinical data through graph neural networks, and creating computational tools for precision medicine. Notable contributions include frameworks like CanMod2 for co-regulatory module inference and CTDPathSim for pathway-based similarity analysis. Bozdag’s work bridges computer science and life sciences, addressing challenges in Alzheimer’s disease diagnosis, cancer systems biology, and plant-microbe interactions. He has pioneered methods for analyzing dynamic biological networks and temporal data patterns, with applications in drug response modeling and electronic health record analysis. His lab develops open-source software tools widely used in computational biology research. Current projects emphasize AI-driven approaches for multi-modal healthcare data fusion, predictive modeling of disease progression, and scalable solutions for big biological data. His research has implications for improving diagnostic accuracy, personalized treatment strategies, and understanding complex biological systems.

Gabriella R. Sterneمشاهده پروفایل

استادیار

• Neuroscience
• Molecular Biology
• Genetics
• +۳ مورد دیگر

Gabriella R. Sterne, Ph.D., is an Assistant Professor in the Department of Biomedical Genetics and the Department of Neuroscience at the University of Rochester School of Medicine and Dentistry (SMD). She holds joint appointments in both departments and leads the Sterne Lab, focused on understanding neural circuit mechanisms underlying feeding behaviors. Dr. Sterne earned her Ph.D. in Neuroscience from the University of Michigan (2016) and a B.A. in Biology from Whitman College (2010). Her research integrates experimental and computational approaches to study how neural circuits coordinate feeding motor programs, time feeding intervals, and store feeding-related memories using Drosophila as a model system. Key research themes include: Feeding Motor Sequences : How circuits orchestrate rhythmic motor actions like proboscis extension. Feeding Microstructure : Neural coding strategies for timing feeding rhythms across timescales. Feeding Memories : Circuit mechanisms linking taste experiences to long-term behavioral adaptations. Her lab collaborates extensively with neuroimaging and computational teams, contributing to projects like the Drosophila connectome mapping. Recent work includes computational brain models and neuroendocrine pathway discoveries influencing feeding behavior. Lab Members include postdoctoral scholars, graduate students (e.g., Gladys Leitch studying hunger modulation), and undergraduates involved in neuroanatomy visualization and synaptic quantification projects. The lab is affiliated with the Biomedical Genetics and Genomics, Neurobiology & Anatomy, and Neuroscience Ph.D. programs. Lab location: KMRB 2-9639, 601 Elmwood Ave, Rochester, NY 14642.

Subramaniam Malarkannanمشاهده پروفایل

استاد

• Immunology
• Cancer Immunotherapy
• NK Cell Biology
• +۳ مورد دیگر

Subramaniam Malarkannan, PhD is a Professor and Gardetto Chair for Immunology and Immunotherapy at the Medical College of Wisconsin. He holds joint appointments in the Department of Microbiology & Immunology, Medicine (Hematology and Oncology), and is a Senior Investigator at Versiti Blood Research Institute. His research focuses on natural killer (NK) cell biology, with emphasis on immunotherapy development, signaling pathways regulation, and metabolic reprogramming in cancer contexts. Malarkannan earned his PhD in Human T Cell Activation from Madurai Kamaraj University (1992). His lab investigates three core areas: 1) CAR-engineered NK cells for cancer therapy with focus on cytokine release syndrome mitigation, 2) spatial-temporal signaling mechanisms via scaffolding proteins like IQGAP1, and 3) metabolic shifts during NK cell activation. Recent work has identified novel signaling pathways critical for cytokine production and cytotoxicity separation. His publications (2022-2025) emphasize translational research in supercharged NK cell therapies, immune microenvironment analysis in pancreatic cancer, and understanding ALS pathogenesis through cytotoxic immune mechanisms. The lab maintains active collaborations across immunology, oncology, and cardiovasculature fields. Key technologies employed include single-cell transcriptomics, genetically modified mouse models, and in vivo tumor efficacy studies. Current efforts aim to develop CRS-free CAR therapies and define metabolic dependencies in immunotherapeutic contexts.

Christopher Klebanoffمشاهده پروفایل

پزشک-پژوهشگر

• Cancer Immunotherapy
• T Cell Immunobiology
• Genetic Engineering of T Cells
• +۲ مورد دیگر

Christopher A. Klebanoff, MD, is a Physician Scientist at Memorial Sloan Kettering Cancer Center (MSK) and an associate member of the Immuno-Oncology Program and Center for Cell Engineering . He holds an MD from Emory University School of Medicine and leads research at the intersection of genetic engineering and T cell immunobiology to advance adoptive T cell therapy (ACT) for solid tumors. His work focuses on overcoming barriers in antigen targeting and T cell persistence. Education : MD, Emory University School of Medicine Research in the Klebanoff Lab applies single-cell sequencing , biophysical TCR analysis , and CRISPR-Cas9 editing to engineer T cells for solid cancer immunotherapy. Key projects address cross-reactivity in neoantigen targeting , intracellular checkpoint inhibition , and public neoantigen discovery across malignancies like colorectal cancer, glioblastoma, and splicing factor mutant leukemias. The lab’s recent publications (2023–2025) reveal novel mechanisms in TCR engineering , CISH deletion to enhance T cell efficacy, and RNA splicing aberrations as sources of immunogenic targets. Articles span preclinical models and first-in-human trials, emphasizing non-viral transduction and HLA genotype screening . Scientific Awards : NIH Fellows Award for Research Excellence (2013) NCI Postdoctoral Fellow of the Year (2011) Howard Hughes Medical Institute Scholarship (2004–2006) AOA National Medical Honor Society (2006) Klebanoff advises collaborations with companies like Achilles Therapeutics and Affini-T Therapeutics , focusing on equity and intellectual property in cellular therapies. His affiliations include the Gerstner Sloan Kettering Graduate School and the Parker Institute for Cancer Immunotherapy .

Nikolay Solovyevمشاهده پروفایل

مدرس

• Analytical Chemistry
• Mass Spectrometry
• Metallomics
• +۷ مورد دیگر

Nikolay Solovyev is a Lecturer in Analytical Chemistry at the Department of Life Sciences, ATU Sligo. He holds a PhD in Natural Sciences from Saint Petersburg State University (2012), focusing on Zeeman modulation polarization spectrometry for toxic element analysis in blood. His research spans metallomics, metabolomics, and neurodegenerative diseases, with a strong emphasis on mass spectrometry techniques (e.g., ICP-MS, GD-TOFMS). Key areas include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and cancer biomarkers. His work contributes to UN Sustainable Development Goals related to health and innovation. Recent studies explore metallome-metabolome interactions in ALS, isotope ratios in disease models, and cultural heritage analysis using proteomics. He has published over 55 peer-reviewed articles, with 22 h-index and 1,496 citations. Solovyev collaborates internationally and supervises PhD students in analytical and biomedical research. His lab develops novel membrane materials and advanced spectrometry methods for environmental and biomedical applications. Notable achievements include pioneering methods for direct quantification of high-ionization elements in solids and elucidating selenium’s role in neural barriers. His research bridges analytical chemistry with clinical and environmental challenges, emphasizing trace element speciation and toxicology.